首頁 > 市場調查報告書 > 製藥

醫藥品法規環境

市場調查報告書

商品編碼

1746489

日本藥物警戒市場報告（按服務提供者、產品生命週期、類型、流程、治療領域、最終用途和地區分類）2025 年至 2033 年

Japan Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 120 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本藥物警戒市場規模達5.027億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到9.761億美元，2025-2033年期間的複合年成長率（CAGR）為7.70%。巨量資料分析、人工智慧和機器學習工具的需求日益成長，這些工具透過實現更有效率的訊號檢測和風險評估，徹底改變了藥物警戒，推動著市場的發展。

藥物警戒是醫療保健和藥物監管的一個重要面向。它涉及對藥物（包括處方藥、疫苗和非處方藥）相關不良反應和安全問題的系統性監測、評估和報告。藥物警戒的主要目標是確保這些產品在整個生命週期內的安全性和有效性。醫療保健專業人員、製藥公司和監管機構在過程中通力合作。他們收集並分析患者和醫療保健提供者報告的不良事件和副作用資料。如果出現潛在的安全問題，可能會採取適當的措施，例如更新產品標籤、發出警告，甚至召回產品，以保護公眾健康。藥物警戒有助於識別先前未知或罕見的不良反應，確保市場上的藥物對病人安全。這種持續的監測和風險評估有助於持續提高藥物安全性和醫療保健的整體品質。

日本藥物警戒市場趨勢：

日本的藥物警戒市場正經歷強勁成長，這主要得益於幾個相互關聯的促進因素。首先，該地區對醫療服務的需求不斷成長，導致藥品消費增加，加劇了對藥品安全進行警惕監測的需求。此外，慢性病盛行率的上升以及新的複雜療法的引入進一步推動了藥物警戒市場的擴張。此外，日本的監管機構正在加強對藥品安全的監管，並對製藥公司施加了嚴格的報告要求。這使得藥物警戒活動必須外包給專業服務提供者，從而推動了市場成長。同時，醫療專業人員和病患對不良事件通報重要性的認知不斷提高，也促使藥物警戒工作力道加大。此外，人工智慧和巨量資料分析等技術的進步透過提高不良事件檢測的效率和準確性，徹底改變了藥物警戒，預計將在預測期內推動日本市場的發展。

日本藥物警戒市場細分：

服務提供者洞察：

內部
合約外包

產品生命週期洞察：

臨床前
第一階段
第二階段
第三階段
第四階段

類型洞察：

自發性報告
強化ADR報告
針對性的自發性報告
群組事件監控
EHR挖掘

流程洞察：

病例資料管理
- 案例記錄
- 案例數據分析
- 醫療審查和報告
訊號檢測
- 不良事件記錄
- 不良事件分析
- 不良事件審查和報告
風險管理系統
- 風險評估系統
- 風險緩解系統

治療領域洞察：

腫瘤學
神經病學
心臟病學
呼吸系統
其他

最終用途洞察：

製藥公司
生技公司
醫療器材公司
其他

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本藥物警戒市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本藥物警戒市場有何影響？
根據服務提供者，日本藥物警戒市場是如何分類的？
根據產品生命週期，日本藥物警戒市場是如何分類的？
日本藥物警戒市場依類型分為哪些類型？
日本藥物警戒市場依流程如何分類？
日本藥物警戒市場如何依治療領域分類？
日本藥物警戒市場如何根據最終用途分類？
日本藥物警戒市場的價值鏈分為哪些階段？
日本藥物警戒的主要促進因素和挑戰是什麼？
日本藥物警戒市場的結構是怎麼樣的？主要參與者是誰？
日本藥物警戒市場的競爭程度如何？

本報告回答的關鍵問題：

日本藥物警戒市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本藥物警戒市場有何影響？
根據服務提供者，日本藥物警戒市場是如何分類的？
根據產品生命週期，日本藥物警戒市場是如何分類的？
日本藥物警戒市場依類型分為哪些類型？
日本藥物警戒市場依流程如何分類？
日本藥物警戒市場如何依治療領域分類？
日本藥物警戒市場如何根據最終用途分類？
日本藥物警戒市場的價值鏈分為哪些階段？
日本藥物警戒的主要促進因素和挑戰是什麼？
日本藥物警戒市場的結構是怎麼樣的？主要參與者是誰？
日本藥物警戒市場的競爭程度如何？

病例資料管理
- 概述
- 市場區隔
  - 案例記錄
  - 案例數據分析
  - 醫療審查和報告
訊號檢測
- 概述
- 市場區隔
  - 不良事件記錄
  - 不良事件分析
  - 不良事件審查和報告
風險管理系統
- 概述
- 市場區隔
  - 風險評估系統
  - 風險緩解系統

第10章：日本藥物警戒市場 - 細分：依治療領域

腫瘤學
- 概述
神經病學
- 概述
心臟病學
- 概述
呼吸系統
- 概述
其他

第 11 章：日本藥物警戒市場 - 分裂：最終用途別

製藥公司
- 概述
生技公司
- 概述
醫療器材公司
- 概述
其他

第 12 章：日本藥物警戒市場 - 競爭格局

概述
市場結構
市場參與者定位
最佳獲勝策略
競爭儀錶板
公司評估象限

第13章：關鍵參與者簡介

Company A

Business Overview
Services Offered
Business Strategies
SWOT Analysis
Major News and Events

Company B

Business Overview
Services Offered
Business Strategies
SWOT Analysis
Major News and Events

Company C

Business Overview
Services Offered
Business Strategies
SWOT Analysis
Major News and Events

Company D

Business Overview
Services Offered
Business Strategies
SWOT Analysis
Major News and Events

Company E

Business Overview
Services Offered
Business Strategies
SWOT Analysis
Major News and Events

第 14 章：日本藥物警戒市場 - 產業分析

促進因素、限制因素和機遇
- 概述
- 驅動程式
- 限制
- 機會
波特五力分析
- 概述
- 買家的議價能力
- 供應商的議價能力
- 競爭程度
- 新進入者的威脅
- 替代品的威脅
價值鏈分析

第 15 章：附錄

簡介目錄

Product Code: SR112025A19290

Japan pharmacovigilance market size reached USD 502.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 976.1 Million by 2033, exhibiting a growth rate (CAGR) of 7.70% during 2025-2033. The increasing demand for big data analytics, artificial intelligence, and machine learning tools, which has revolutionized pharmacovigilance by enabling more efficient signal detection and risk assessment, is driving the market.

Pharmacovigilance is a crucial aspect of healthcare and drug regulation. It involves the systematic monitoring, assessment, and reporting of adverse effects and safety concerns associated with pharmaceutical products, including prescription medications, vaccines, and over-the-counter drugs. The primary goal of pharmacovigilance is to ensure the safety and effectiveness of these products throughout their lifecycle. Healthcare professionals, pharmaceutical companies, and regulatory agencies collaborate in this process. They collect and analyze data on adverse events and side effects reported by patients and healthcare providers. If a potential safety concern arises, appropriate actions, such as product labeling updates, warnings, or even product recalls, may be taken to protect public health. Pharmacovigilance helps identify previously unknown or rare adverse effects, ensuring that drugs on the market remain safe for patients. This ongoing monitoring and risk assessment contribute to the continuous improvement of drug safety and the overall quality of healthcare.

Japan Pharmacovigilance Market Trends:

The pharmacovigilance market in Japan is experiencing robust growth, primarily due to several interconnected drivers. Firstly, the escalating regional demand for healthcare services has led to an increased consumption of medicines, amplifying the need for vigilant monitoring of drug safety. Additionally, the rising prevalence of chronic diseases and the introduction of new and complex therapies have further fueled the expansion of the pharmacovigilance market. Moreover, regulatory agencies in Japan are tightening their oversight of drug safety, imposing stringent reporting requirements on pharmaceutical companies. This has necessitated the outsourcing of pharmacovigilance activities to specialized service providers, driving market growth. Simultaneously, the growing awareness among healthcare professionals and patients about the importance of adverse event reporting has led to increased pharmacovigilance efforts. Moreover, advancements in technology, including artificial intelligence and big data analytics, which have revolutionized pharmacovigilance by enhancing the efficiency and accuracy of adverse event detection, are expected to drive the market in Japan during the forecast period.

Japan Pharmacovigilance Market Segmentation:

Service Provider Insights:

In-house
Contract Outsourcing

Product Life Cycle Insights:

Pre-clinical
Phase I
Phase II
Phase III
Phase IV

Type Insights:

Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

Process Flow Insights:

Case Data Management
- Case Logging
- Case Data Analysis
- Medical Reviewing and Reporting
Signal Detection
- Adverse Event Logging
- Adverse Event Analysis
- Adverse Event Review and Reporting
Risk Management System
- Risk Evaluation System
- Risk Mitigation System

Therapeutic Area Insights:

Oncology
Neurology
Cardiology
Respiratory Systems
Others

End Use Insights:

Pharmaceuticals Companies
Biotechnology Companies
Medical Device Companies
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan pharmacovigilance market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan pharmacovigilance market?
What is the breakup of the Japan pharmacovigilance market on the basis of service provider?
What is the breakup of the Japan pharmacovigilance market on the basis of product life cycle?
What is the breakup of the Japan pharmacovigilance market on the basis of type?
What is the breakup of the Japan pharmacovigilance market on the basis of process flow?
What is the breakup of the Japan pharmacovigilance market on the basis of therapeutic area?
What is the breakup of the Japan pharmacovigilance market on the basis of end use?
What are the various stages in the value chain of the Japan pharmacovigilance market?
What are the key driving factors and challenges in the Japan pharmacovigilance?
What is the structure of the Japan pharmacovigilance market and who are the key players?
What is the degree of competition in the Japan pharmacovigilance market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmacovigilance Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pharmacovigilance Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Pharmacovigilance Market - Breakup by Service Provider

6.1 In-house
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Contract Outsourcing
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)

7 Japan Pharmacovigilance Market - Breakup by Product Life Cycle

7.1 Pre-clinical
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Phase I
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Phase II
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Phase III
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Phase IV
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)

8 Japan Pharmacovigilance Market - Breakup by Type

8.1 Spontaneous Reporting
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Intensified ADR Reporting
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Targeted Spontaneous Reporting
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Cohort Event Monitoring
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 EHR Mining
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2019-2024)
- 8.5.3 Market Forecast (2025-2033)

9 Japan Pharmacovigilance Market - Breakup by Process Flow

9.1 Case Data Management
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Segmentation
  - 9.1.3.1 Case Logging
  - 9.1.3.2 Case Data Analysis
  - 9.1.3.3 Medical Reviewing and Reporting
- 9.1.4 Market Forecast (2025-2033)
9.2 Signal Detection
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Segmentation
  - 9.2.3.1 Adverse Event Logging
  - 9.2.3.2 Adverse Event Analysis
  - 9.2.3.3 Adverse Event Review and Reporting
- 9.2.4 Market Forecast (2025-2033)
9.3 Risk Management System
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Segmentation
  - 9.3.3.1 Risk Evaluation System
  - 9.3.3.2 Risk Mitigation System
- 9.3.4 Market Forecast (2025-2033)

10 Japan Pharmacovigilance Market - Breakup by Therapeutic Area

10.1 Oncology
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2019-2024)
- 10.1.3 Market Forecast (2025-2033)
10.2 Neurology
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2019-2024)
- 10.2.3 Market Forecast (2025-2033)
10.3 Cardiology
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2019-2024)
- 10.3.3 Market Forecast (2025-2033)
10.4 Respiratory Systems
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2019-2024)
- 10.4.3 Market Forecast (2025-2033)
10.5 Others
- 10.5.1 Historical and Current Market Trends (2019-2024)
- 10.5.2 Market Forecast (2025-2033)

11 Japan Pharmacovigilance Market - Breakup by End Use

11.1 Pharmaceuticals Companies
- 11.1.1 Overview
- 11.1.2 Historical and Current Market Trends (2019-2024)
- 11.1.3 Market Forecast (2025-2033)
11.2 Biotechnology Companies
- 11.2.1 Overview
- 11.2.2 Historical and Current Market Trends (2019-2024)
- 11.2.3 Market Forecast (2025-2033)
11.3 Medical Device Companies
- 11.3.1 Overview
- 11.3.2 Historical and Current Market Trends (2019-2024)
- 11.3.3 Market Forecast (2025-2033)
11.4 Others
- 11.4.1 Historical and Current Market Trends (2019-2024)
- 11.4.2 Market Forecast (2025-2033)

12 Japan Pharmacovigilance Market - Competitive Landscape

12.1 Overview
12.2 Market Structure
12.3 Market Player Positioning
12.4 Top Winning Strategies
12.5 Competitive Dashboard
12.6 Company Evaluation Quadrant

13 Profiles of Key Players

13.1 Company A
- 13.1.1 Business Overview
- 13.1.2 Services Offered
- 13.1.3 Business Strategies
- 13.1.4 SWOT Analysis
- 13.1.5 Major News and Events
13.2 Company B
- 13.2.1 Business Overview
- 13.2.2 Services Offered
- 13.2.3 Business Strategies
- 13.2.4 SWOT Analysis
- 13.2.5 Major News and Events
13.3 Company C
- 13.3.1 Business Overview
- 13.3.2 Services Offered
- 13.3.3 Business Strategies
- 13.3.4 SWOT Analysis
- 13.3.5 Major News and Events
13.4 Company D
- 13.4.1 Business Overview
- 13.4.2 Services Offered
- 13.4.3 Business Strategies
- 13.4.4 SWOT Analysis
- 13.4.5 Major News and Events
13.5 Company E
- 13.5.1 Business Overview
- 13.5.2 Services Offered
- 13.5.3 Business Strategies
- 13.5.4 SWOT Analysis
- 13.5.5 Major News and Events

14 Japan Pharmacovigilance Market - Industry Analysis

14.1 Drivers, Restraints, and Opportunities
- 14.1.1 Overview
- 14.1.2 Drivers
- 14.1.3 Restraints
- 14.1.4 Opportunities
14.2 Porters Five Forces Analysis
- 14.2.1 Overview
- 14.2.2 Bargaining Power of Buyers
- 14.2.3 Bargaining Power of Suppliers
- 14.2.4 Degree of Competition
- 14.2.5 Threat of New Entrants
- 14.2.6 Threat of Substitutes
14.3 Value Chain Analysis